In this interactive, 30-minute activity, head and neck squamous cell cancer (HNSCC) experts discuss the rationale for targeting the immune system in HNSCC, the evidence for immune checkpoint inhibitors for recurrent and metastatic HNSCC, and the potential impact of biomarkers on response to immunotherapy. In addition, an actual patient with HNSCC provides insight on his experience from diagnosis through treatment with immunotherapy.
0.5 AMA PRA Category 1 Credit™
May 19, 2017
May 19, 2018
Ezra Cohen, MD, FRCPSC, FASCOUC San Diego Health
San Diego, California, United States
Robert Haddad, MDDana-Farber Cancer Institute
Boston, Massachusetts, United States
Andrew Sikora, MD, PhDBaylor College of Medicine
Houston, Texas, United States
- Why immunotherapy in head and neck cancer?
- Use of immune checkpoint inhibitors in HNSCC: What have we learned so far?
- Next steps for immunotherapy in head and neck cancer
- Patient perspective
- prIME Points™
This educational activity is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.
After successful completion of this educational activity, participants should be able to:
- Describe the rationale for targeting the immune system in HNSCC
- Evaluate efficacy and safety data of immune checkpoint inhibitors in recurrent and metastatic HNSCC and identify patients that may benefit from this treatment
- Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
- Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
- Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer
This activity is supported through an educational grant from Bristol-Myers Squibb.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Cohen has disclosed that he has received consulting fees from AstraZeneca; Bristol-Myers Squibb; Eisai; Human Longevity, Inc.; Merck; and Pfizer. He has disclosed that he has ownership interest in Human Longevity, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Mr Hasse has disclosed that he has been enrolled in a clinical trial for Bristol-Myers Squibb.
Dr Haddad has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, Merck, and Pfizer. He has disclosed that he has performed contract research for AstraZeneca, Bristol-Myers Squibb, Celgene, Merck, and Pfizer. He also disclosed receipt of royalties from UpToDate. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Sikora has disclosed that he has received consulting fees from Tessa Therapeutics. He has disclosed that he has performed contract research for Advaxis and that he is a patent holder included in patents filed by Baylor College of Medicine. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.